^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD0120

    i
    Other names: AZD0120, GC012F, GC012, Dual CAR-BCMA-19, BCMA/CD19 dual-target CAR-T cell immunotherapy, AZD-0120, GC-012, GC-012F, AZD 0120, GC 012, GC 012F
    Company:
    AstraZeneca
    Drug class:
    CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
    Related drugs:
    1d
    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting | N=118 --> 20
    Enrollment closed • Enrollment change
    |
    AZD0120
    7d
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB | N=38 --> 153
    Enrollment change
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    9d
    Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients (clinicaltrials.gov)
    P1, N=18, Recruiting, RenJi Hospital | Trial completion date: May 2025 --> Jun 2029 | Trial primary completion date: Nov 2023 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    AZD0120
    1m
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=153, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    1m
    D8311C00001: A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. (2025-523285-25-00)
    P2/3, N=38, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • AZD0120
    2ms
    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants (clinicaltrials.gov)
    P1, N=12, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SDC1 (Syndecan 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    AZD0120
    2ms
    A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1/2, N=118, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Phase classification: P1 --> P1/2 | N=18 --> 118
    Phase classification • Enrollment change
    |
    AZD0120
    2ms
    AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (clinicaltrials.gov)
    P1/2, N=182, Recruiting, AstraZeneca | N=80 --> 182
    Enrollment change
    |
    AZD0120
    3ms
    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (clinicaltrials.gov)
    P3, N=508, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Apr 2029 --> Jul 2030
    Enrollment open • Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    3ms
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120
    4ms
    AURORA: A Study of AZD0120 in Autoimmune Diseases (clinicaltrials.gov)
    P1, N=27, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD0120
    4ms
    DURGA-4: A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma. (clinicaltrials.gov)
    P3, N=508, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120